Introduction
============

Three papers published concurrently in the October issue of *Nature Medicine*have demonstrated new links between mitogenic cytokine signalling and the cell cycle inhibitor p27^KIP1^, and have elucidated how this link may contribute to breast cancer patient prognosis \[[@B1]-[@B3]\].

Cell cycle control occurs through cyclin binding to the cyclin-dependent kinases (CDKs) that stimulate G1 progression \[[@B4]\]. p27^KIP1^is a member of the kinase inhibitor protein (KIP) family that inhibit cell cycle progression by binding to cyclin-CDK complexes \[[@B5]\]. In cancers where protein kinase B (PKB)/Akt is constitutively activated by upstream oncogenes, Akt decreases p27^KIP1^by increasing proteolysis and reducing transcription \[[@B6]\].

These three articles describe a third way in which Akt resists G1 arrest, namely by a p27^KIP1^phosphorylation that impairs nuclear import and prevents its inhibition of cyclin-CDK complexes. The authors of these studies conclude that exclusion of p27^KIP1^from the nucleus leads to a poor patient outcome in breast cancer \[[@B1]-[@B3]\].

p27^KIP1^phosphorylation leads to cytoplasmic localisation
==========================================================

Wild type and constitutively active Akt were both shown to phosphorylate p27^KIP1^at threonine157, leading to cytoplasmic localisation of p27^KIP1^. Blockade of Akt activation by the phosphatidyl inositol 3\'-kinase (PI3K) inhibitor LY294002, or transfection with the mutant p27^KIP1^-T157A, led to nuclear p27^KIP1^localisation. Constitutively active Akt prevented wild type p27^KIP1^, but not p27^KIP1^-T157A, from causing G1 arrest.

In two of the studies it was reported that approximately 40% of primary breast tumours displayed cytoplasmic p27^KIP1^staining \[[@B1],[@B3]\]. The presence of cytoplasmic p27^KIP1^in human breast cancers was highly correlated with Akt activation. The best prognostic subgroup of breast tumours had strong, exclusively nuclear p27^KIP1^staining, while cancers with lower expression levels, but cytoplasmic localisation, had the worst survival rates.

The data indicate that p27^KIP1^normally acts as a tumour suppressor protein, but that the oncogenic activation of Akt leads to mislocation of p27^KIP1^to the cytoplasm where it is unable to inhibit cell cycle proteins. The study indicates that cytoplasmic location of p27^KIP1^in breast tumours is a prognostic indicator and that the Akt pathway may be a good target for anti-cancer therapy.

Conclusion
==========

p27^KIP1^is an inhibitor of cell cycle progression that is rarely mutated or silenced in cancers. The *Nature Medicine*articles demonstrate that p27^KIP1^depends on a nuclear location to perform its cell cycle inhibitory function and that Akt phosphorylates p27^KIP1^leading to its mislocalisation in the cytoplasm \[[@B1]-[@B3]\].

Akt lies downstream of PI3K and the growth factor receptors epidermal growth factor receptor (EGFR) and ErbB2, which act as oncogenes in numerous cancers \[[@B7]\]. This means that Akt is commonly activated in many forms of cancer \[[@B8]\]. All three of these studies confirm that the action of Akt on p27^KIP1^localisation appears crucial to breast tumour progression \[[@B1]-[@B3]\]. There is evidence that Akt can also exclude nuclear presence of another cell cycle inhibitor, p21^CIP1^\[[@B9]\]. It will be interesting to see whether the cellular location of p21^CIP1^will add to the prognostic information given by p27^KIP1^in cancers.

Finally, the articles suggest new therapeutic opportunities in targeting Akt or the p27^KIP1^phosphorylation site to relocate p27^KIP1^to the nucleus and improve the long-term prognosis of breast cancer patients in whom this important cell cycle regulator is mislocated.
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CDK = cyclin-dependant kinase; KIP = kinase inhibitor protein; PKB = protein kinase B; PI3K = phosphatidyl inositol 3\'-kinase.
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